MARKET

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.73
+0.16
+2.11%
Closed 16:00 11/14 EST
OPEN
7.85
PREV CLOSE
7.57
HIGH
7.89
LOW
7.68
VOLUME
5.42K
TURNOVER
--
52 WEEK HIGH
17.34
52 WEEK LOW
4.560
MARKET CAP
103.68M
P/E (TTM)
-0.6056
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MLND and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MLND News

  • Millendo Therapeutics Q3 EPS $(0.87) May Not Compare $(10.61) YoY
  • Benzinga.1d ago
  • Millendo Therapeutics Reports Third Quarter 2019 Operating and Financial Results
  • Business Wire.1d ago
  • Millendo Therapeutics Completes Patient Recruitment for Pivotal Study of Livoletide in Prader-Willi Syndrome
  • Business Wire.1d ago
  • Millendo Therapeutics to Present at the Stifel 2019 Healthcare Conference
  • Business Wire.3d ago

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About MLND

Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.
More

Webull offers Millendo Therapeutics Inc (MLND) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.